Key Points
· Evaluation should begin with careful clinical suspicion and complete imaging before any biopsy is attempted.
· Biopsy planning is part of treatment planning and should be carried out by, or in close coordination with, the team responsible for definitive surgery.
· Management is guided by histology, grade, local extent, metastatic status, resectability, and the functional value of limb salvage.
· Across most malignant musculoskeletal tumors, the strongest adverse prognostic features are metastatic disease at presentation, high grade, large size, axial location, inadequate margins, poor treatment response, and local recurrence.
· Limb salvage is desirable, but only when oncologic safety is preserved and a durable, functional reconstruction is realistic.
Introduction
Malignant musculoskeletal tumors include primary malignant bone tumors, soft tissue sarcomas, hematologic malignancies involving bone, and metastatic bone disease. Although each group has its own biology and preferred treatment pathway, the practical approach remains similar: recognize the possibility of malignancy, complete local and systemic staging, obtain a properly planned biopsy, define the histologic diagnosis, discuss the case in a multidisciplinary setting, and proceed with definitive local and systemic treatment followed by structured surveillance.
Treatment Algorithm
1. Recognize the possibility of malignancy
· Persistent deep pain, especially night pain, should raise suspicion even in the absence of trauma.
· An enlarging mass, unexplained swelling, pathologic fracture, or pain out of proportion to the initial complaint should be treated cautiously.
· Aggressive imaging findings include a permeative or moth-eaten pattern, cortical destruction, wide zone of transition, periosteal reaction, soft-tissue extension, and a large deep soft-tissue lesion.
2. Complete imaging and staging before biopsy
· Plain radiographs remain the first study for suspected bone lesions and often provide the first clue to aggressiveness.
· MRI of the entire involved bone or compartment is essential for defining intramedullary extent, soft-tissue spread, skip lesions, and the relationship to neurovascular structures.
· CT is useful when cortical anatomy, mineralization, or complex pelvic or axial anatomy must be defined in greater detail.
· Chest CT is standard in sarcoma staging because the lung is the most common site of distant spread in many primary bone and soft tissue malignancies.
· Bone scan or PET/CT may be added selectively depending on histology and concern for multifocal or metastatic disease.
3. Plan the biopsy as part of definitive treatment
· The biopsy tract must be placed so that it can be removed en bloc at the time of definitive resection.
· Image-guided core needle biopsy is often sufficient and helps limit contamination.
· Incisional biopsy is appropriate when core biopsy is nondiagnostic or tissue architecture is especially important.
· Unplanned biopsy or casual excision of a suspicious lesion can contaminate uninvolved tissue planes and may convert a salvageable case into one requiring more radical surgery.
4. Histology-specific definitive treatment
Primary bone sarcomas
· Osteosarcoma is usually treated with neoadjuvant chemotherapy, wide resection, and postoperative chemotherapy.
· Ewing sarcoma is typically managed with multidrug systemic therapy combined with local control through surgery, radiotherapy, or both.
· Conventional chondrosarcoma is primarily a surgical disease; chemotherapy and radiotherapy generally have limited value except in selected aggressive variants.
Soft tissue sarcomas
· Wide resection is the main treatment for resectable disease.
· Radiotherapy is frequently used to improve local control in intermediate- and high-grade tumors.
· Chemotherapy has a selective role, especially in chemosensitive histologies, large high-risk tumors, or metastatic disease.
Metastatic bone disease
· The treatment goal is not the same as in primary sarcoma; the focus is pain relief, fracture prevention, durable fixation, and rapid restoration of function.
· Management depends on the biology of the primary tumor, systemic disease burden, expected survival, and whether the lesion represents an impending or completed fracture.
· Fixation should be durable enough for the patient’s remaining lifespan because metastatic lesions often do not heal reliably.
5. Surgical decision-making
· Limb salvage is preferred when negative margins can be obtained and the reconstructed limb is likely to remain useful.
· Amputation remains appropriate when margins would be inadequate, major neurovascular structures are extensively involved, contamination is severe, infection is uncontrolled, or salvage would leave a nonfunctional extremity.
· Margin quality is central to local control. A technically impressive reconstruction never compensates for inadequate oncologic clearance.
6. Surveillance
· Follow-up is directed at early recognition of local recurrence, pulmonary metastasis, reconstruction failure, and treatment-related complications.
· The first two to three years are generally the most intensive period of surveillance, especially in high-grade lesions.
Prognostic Factors
Prognosis is shaped by a combination of tumor biology, anatomic extent, treatment quality, and disease behavior after therapy. Some variables are histology-specific, but several adverse features recur consistently across bone sarcoma, soft tissue sarcoma, and metastatic bone involvement.
1. Tumor-related factors
· Metastatic disease at presentation is one of the strongest negative prognostic factors in nearly every malignant musculoskeletal tumor category.
· High histologic grade is closely associated with metastatic potential, recurrence, and reduced survival.
· Large tumor size or volume generally indicates more aggressive behavior and a lower likelihood of durable control.
· Axial and pelvic tumors often fare worse than appendicular lesions because diagnosis is delayed, resection is technically more difficult, and wide margins are harder to obtain.
· Extensive local disease, including neurovascular involvement, joint invasion, multicompartment spread, skip lesions, or a pathologic fracture, complicates treatment and may worsen outcome.
· Histologic subtype matters. For example, dedifferentiated chondrosarcoma behaves far more aggressively than low-grade conventional chondrosarcoma.
2. Treatment-related factors
· A properly planned biopsy protects future surgical options, while a poorly placed biopsy may contaminate compartments and compromise local control.
· Negative surgical margins remain one of the clearest predictors of successful local treatment.
· Histologic response to preoperative chemotherapy, particularly the degree of tumor necrosis in osteosarcoma, carries clear prognostic significance.
· Reliable local control, whether achieved by surgery alone or by surgery combined with radiotherapy, is critical to long-term outcome.
3. Recurrence-related factors
· Local recurrence is rarely an isolated technical problem; it often reflects aggressive biology, inadequate margins, or both.
· Early recurrence is generally more ominous than late recurrence.
· Pulmonary recurrence in selected sarcoma patients may still be approached aggressively, but multifocal recurrence usually signals poor prognosis.
Tumor-Specific Highlights
Osteosarcoma
· Favorable features include localized disease, extremity location, complete resection, and good histologic response to neoadjuvant chemotherapy.
· Adverse features include metastasis at diagnosis, large tumor burden, axial location, poor chemotherapy response, and local recurrence.
Ewing sarcoma
· Localized disease, smaller tumor volume, extremity location, and good response to induction treatment are favorable signs.
· Pelvic site, metastasis at presentation, and poor response to systemic therapy are well-known adverse features.
Chondrosarcoma
· Grade is the most important prognostic variable.
· High-grade, dedifferentiated, axial, and margin-positive tumors behave more aggressively and recur more often.
Soft tissue sarcoma
· High grade, deep location, larger size, positive margins, and local recurrence are among the most important adverse factors.
· Radiotherapy improves local control, while systemic therapy is reserved for selected indications rather than used routinely in every case.
Metastatic bone disease
· Outcome depends mainly on primary tumor biology, systemic disease burden, and patient performance status rather than the skeletal lesion alone.
· Patients with limited disease, better performance status, and more favorable primary tumors may benefit from more durable and aggressive reconstruction strategies.
Practical Pearls
· Do not biopsy a suspicious tumor before full imaging is obtained.
· The biopsy tract should always be considered expendable and included in the definitive surgical field.
· Any enlarging or deep soft-tissue mass should be treated as a sarcoma until proven otherwise.
· In metastatic bone disease, choose an implant that will last; biological healing is often unreliable.
· Oncologic adequacy always comes before cosmetic or reconstructive ambition.
Conclusion
The management of malignant musculoskeletal tumors follows a disciplined sequence: recognition, staging, biopsy, diagnosis, multidisciplinary planning, definitive treatment, and surveillance. Although the details differ among osteosarcoma, Ewing sarcoma, chondrosarcoma, soft tissue sarcoma, and metastatic bone disease, the same fundamentals remain true. Early suspicion, correct biopsy technique, sound margin-based surgery, and thoughtful integration of systemic and radiation therapy are what ultimately determine outcome. From a prognostic standpoint, metastatic status, tumor grade, size, location, response to treatment, and local recurrence remain the variables that matter most.
References
1. Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79-iv95.
2. Soft Tissue and Visceral Sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348-1365.
3. WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. 5th ed. Lyon: IARC Press; 2020.
4. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;(153):106-120.
5. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015;33(27):3029-3035.
6. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: Current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036-3046.
7. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20(3):776-790.
8. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108-3114.
9. Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320-329.
10. Mirels H. Metastatic disease in long bones: A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989;(249):256-264.